Reply to Letter to the Editor on Mease et al.

We read with interest the Letter to the Editor by Kerschbaumer et al regarding our article on the primary results from the SEAM-PsA trial (1). We appreciated the comments highlighting the methotrexate (MTX) monotherapy results. Since MTX is a drug that has been long used in psoriatic arthritis (PsA) without much data from rigorous and well-controlled clinical trials, we sought to provide reliable data about MTX through SEAM-PsA.